<?xml version="1.0" encoding="UTF-8"?>
<p>Group A rotaviruses (RVAs) belong to family 
 <italic>Reoviridae</italic> are the leading cause of fatal dehydrating diarrhea in infants and young children worldwide particularly in the developing countries of Africa and Asia [
 <xref rid="pone.0220387.ref001" ref-type="bibr">1</xref>â€“
 <xref rid="pone.0220387.ref004" ref-type="bibr">4</xref>]. The rotavirus is a 11 segmented double-stranded RNA (dsRNA) virus encoding six structural proteins (VP1-VP4, VP6, VP7) and six non-structural proteins (NSP1-NSP6) [
 <xref rid="pone.0220387.ref005" ref-type="bibr">5</xref>]. The segmented nature of its genome allows RVs to adopt remarkable genetic diversity [
 <xref rid="pone.0220387.ref006" ref-type="bibr">6</xref>]. Based on the sequence of VP7 and VP4 genes, RVAs are classified into G and P-genotypes, respectively. Currently, 36 G and 51 P-types have been reported worldwide [
 <xref rid="pone.0220387.ref007" ref-type="bibr">7</xref>]. The most common G/P genotype combinations causing 90% infections in in humans are G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and G12P[8] [
 <xref rid="pone.0220387.ref008" ref-type="bibr">8</xref>,
 <xref rid="pone.0220387.ref009" ref-type="bibr">9</xref>]. Vaccination is an effective measure to combat RVA infections. Two live oral rotavirus vaccines (Rotarix, GlaxoSmithKline and RotaTeq, Merck &amp; Co) have been licensed and are available in the market since 2006 [
 <xref rid="pone.0220387.ref010" ref-type="bibr">10</xref>,
 <xref rid="pone.0220387.ref011" ref-type="bibr">11</xref>]. Rotarix is a monovalent oral live-attenuated vaccine and RotaTeq is a pentavalent human-bovine reassortant vaccine [
 <xref rid="pone.0220387.ref012" ref-type="bibr">12</xref>].
</p>
